Jazz Pharmaceuticals Denmark ApS: Financial statements 2025
CVR: 39791447
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
Jazz Pharmaceuticals Denmark ApS (CVR 39791447) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK 41,044,332 and a net result of DKK 1,528,396 compared with DKK 1,538,214 the year before. That is an increase of 11.8% compared with the year before. Equity in the 2025 report amounted to DKK 13,823,507. The solvency ratio was 30.7%. The company had 19 employees in the financial year.
- Gross Profit
- DKK 41,044,332
- Profit/Loss
- DKK 1,528,396
- Equity
- DKK 13,823,507
- Total Assets
- DKK 45,021,461
- Employees
- 19
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | 41 mio. | 1.5 mio. | 13.8 mio. | 19 |
| 2024 | - | 36.7 mio. | 1.5 mio. | 12.3 mio. | 18 |
| 2023 | - | 31.8 mio. | 595 t. | 10.8 mio. | 17 |
| 2022 | - | 30.4 mio. | 2 mio. | 10.2 mio. | 16 |
| 2021 | - | 21.7 mio. | 560 t. | 8.2 mio. | 10 |
Official annual report
How creditworthy is Jazz Pharmaceuticals Denmark ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
Jazz Pharmaceuticals Denmark ApS has published its annual report for 2024. Gross profit came to DKK 36,708,802, and the net result was DKK 1,538,214.
As of January 17, 2025, David James Spackman is registered as director of Jazz Pharmaceuticals Denmark ApS.
As of January 17, 2025, Samantha Jane Laura Pearce has stepped down as director of Jazz Pharmaceuticals Denmark ApS.
Jazz Pharmaceuticals Denmark ApS has won the tender "Amgros 2025 1.711.b" issued by Amgros I/S worth 12,800,000 DKK.
About Jazz Pharmaceuticals Denmark ApS
Jazz Pharmaceuticals Denmark ApS is a Danish company of the type Anpartsselskab based in København V, founded in 2018. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of David James Spackman and Kamilla Enggaard Have. The company is owned by Jazz Pharmaceuticals Ireland Holdings Limited. The company has 13 employees (2026). In 2025, the company reported a gross profit of DKK 41,044,332 and a net result of DKK 1,528,396 compared with DKK 1,538,214 the year before. Equity in the 2025 report amounted to DKK 13,823,507.